Reduction of the Dietary Glycemic Index (GI) by L-Arabinose and Indigestible Dextrin
NCT ID: NCT01039662
Last Updated: 2011-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
19 participants
INTERVENTIONAL
2009-12-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Fiber on Glycemic Index
NCT02615327
Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia
NCT04877366
Glycemic Response to Oral Nutrition Supplements
NCT02612675
Glycemic Response in Persons with Type 2 Diabetes
NCT04413357
Glycemic Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus
NCT02898766
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oolong tea containing L-arabinose and indigestible dextrin
L-arabinose and indigestible dextrin
Oolong tea
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
L-arabinose and indigestible dextrin
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI is less or equal to 30 kg/m2
* Willing not to serve as blood donor during the study
* Informed consent signed
Exclusion Criteria
* Female subjects who are pregnant or nursing a child
* Participation in any clinical trial up to 90 days before Day 1 of this study
* Renal or hepatic dysfunction
* Heart disease
* Under medication
20 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Unitika Ltd.
INDUSTRY
Hiroshima University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hiroshima University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hiroshima University
Hiroshima, Hiroshima, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
eki-199
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.